Other factors such as multiple comorbidities (HR: 1.01; 95% CI: 0.48-2.17), gender (HR: 1.18; 95% CI: 0.68-2.05), high serum CA 19-9 level (HR: 1.09; 95% CI: 0.64-1.84), higher serum CEA level (HR: 1.27; 95% CI: 0.75-2.15), and poorly differentiated tumor grade (OR: 1.81; 95% CI: 0.80-4.09) were associated with worsen survival but were not statistically significant (all p-values >0.05) (Table 4). The gene discussed is CEACAM5; the disease is neoplasm.